I have been wondering about this too and I'm sure it is covered off in earlier threads, but I went googling anyway.
I managed to find a document produced by the Australian Department of Health titled:
"Compounded medicines and good manufacturing practice (GMP) Guide to the interpretation of the PIC/S guide to GMP for compounded medicinal products" Version 3.0, September 2020
It is here FYI: https://consultations.health.gov.au/tga/compounded-medicines-and-gmp/supporting_documents/consultationcompoundedmedicinesandgoodmanufacturingpracticegmp.DOCX
This section appears relevant and would imply that Zilosul (once approved) would/should stop the compounding of injectable ElmironAppropriate circumstances for compounding medicines
Only prepare a compounded medicine in circumstances where:
•an appropriate commercial product is not available
•a commercial product is not suitable (e.g. if a patient experienced an allergy to an excipient in the commercial product), or
•when undertaking research sanctioned by a recognised human research ethics committee.
The compounding of a medicine (whether prescribed or not) should not take place when it would both:
•be a close formulation to an available and suitable commercial product
•would not be likely to produce a different therapeutic outcome to the commercial product.
In this situation, notify the prescriber that this medicine cannot be compounded under these circumstances.
DYOR - my thoughts only ;-)
- Forums
- ASX - By Stock
- research reports and media
I have been wondering about this too and I'm sure it is covered...
-
- There are more pages in this discussion • 2,165 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
25.5¢ |
Change
-0.005(1.92%) |
Mkt cap ! $89.19M |
Open | High | Low | Value | Volume |
27.0¢ | 27.0¢ | 25.5¢ | $261.4K | 990.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9999 | 25.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
26.0¢ | 9445 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9999 | 0.255 |
5 | 259000 | 0.250 |
4 | 96000 | 0.245 |
9 | 261374 | 0.240 |
5 | 71970 | 0.235 |
Price($) | Vol. | No. |
---|---|---|
0.260 | 9445 | 1 |
0.275 | 44000 | 2 |
0.280 | 35900 | 3 |
0.285 | 6729 | 2 |
0.290 | 60000 | 2 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online